Literature DB >> 20620978

Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches.

Vicki A Morrison1.   

Abstract

Infectious complications continue to be a major cause of morbidity and mortality in patients with chronic lymphocytic leukaemia (CLL). The pathogenesis of infections in these patients is multifactorial, related to inherent immune defects and therapy-related immunosuppression. Hypogammaglobulinaemia is an important predisposing factor for infection in all patients. The use of the purine analogues such as fludarabine, and monoclonal antibodies such as rituximab and alemtuzumab, has introduced a new spectrum of infectious complications caused by pathogens such as Pneumocystis, Listeria, mycobacteria, herpesviruses Candida and Aspergillus, related to the cellular immune suppression induced by these agents. This review focuses on the pathogenesis and risk factors for infections in patients with CLL, the spectrum of infectious complications and preventive approaches to infection in these patients, using antimicrobial and immunoglobulin prophylaxis and vaccination strategies. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620978     DOI: 10.1016/j.beha.2009.12.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  40 in total

1.  Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia.

Authors:  Vesa Lindström; Janne Aittoniemi; Urpu Salmenniemi; Helena Käyhty; Heini Huhtala; Maija Itälä-Remes; Marjatta Sinisalo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

2.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Authors:  Jennifer A Woyach; Kelly Smucker; Lisa L Smith; Arletta Lozanski; Yiming Zhong; Amy S Ruppert; David Lucas; Katie Williams; Weiqiang Zhao; Laura Rassenti; Emanuela Ghia; Thomas J Kipps; Rose Mantel; Jeffrey Jones; Joseph Flynn; Kami Maddocks; Susan O'Brien; Richard R Furman; Danelle F James; Fong Clow; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

3.  IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Authors:  S Drennan; A D'Avola; Y Gao; C Weigel; E Chrysostomou; A J Steele; T Zenz; C Plass; P W Johnson; A P Williams; G Packham; F K Stevenson; C C Oakes; F Forconi
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

Review 4.  Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.

Authors:  Clive S Zent; Neil E Kay
Journal:  Leuk Lymphoma       Date:  2011-06-08

5.  Outcomes in critically ill chronic lymphocytic leukemia patients.

Authors:  Aliénor Xhaard; Loic Epelboin; David Schnell; François Vincent; Vincent Levy; Marion Malphettes; Elie Azoulay; Michaël Darmon
Journal:  Support Care Cancer       Date:  2013-02-15       Impact factor: 3.603

6.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

7.  IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.

Authors:  Ganchimeg Ishdorj; Erin Streu; Pascal Lambert; Harbhajan S Dhaliwal; Salaheddin M Mahmud; Spencer B Gibson; Versha Banerji; Aaron J Marshall; James B Johnston
Journal:  Blood Adv       Date:  2019-07-23

8.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 9.  Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

Authors:  Fatima Dhalla; Mary Lucas; Anna Schuh; Malini Bhole; Rashmi Jain; Smita Y Patel; Siraj Misbah; Helen Chapel
Journal:  J Clin Immunol       Date:  2014-02-21       Impact factor: 8.317

10.  Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.

Authors:  Inhye E Ahn; Theresa Jerussi; Mohammed Farooqui; Xin Tian; Adrian Wiestner; Juan Gea-Banacloche
Journal:  Blood       Date:  2016-08-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.